Lam Research Stock Higher On Needham & Company Price Hike

Lam Research stock is in a strong uptrend. On October 19, 2017, Needham & Company, one of the best analysts on Wall Street, raised their price target on Lam Research to $235 from $220 which represents 17.2% upside from the current price.

There are a whopping 17 analyst Buy ratings on Lam Research stock.
Continue reading “Lam Research Stock Higher On Needham & Company Price Hike”

Taiwan Semiconductor Beats On Earnings and Revenue

Taiwan Semiconductor Manufacturing announced its quarterly results on Thursday, October 19, 2017. The company reported EPS of $3.47 versus the consensus estimate of $0.56. Revenue also beat coming in at $252.11 billion versus the consensus estimate of $249.49 billion.
Continue reading “Taiwan Semiconductor Beats On Earnings and Revenue”

KeyCorp Stock Bullish Flag Flush On Analyst Buy Rating

KeyCorp stock flushed today forming a bullish hammer, inside a Bullish Flag pattern. KeyCorp had its Buy rating reaffirmed by Keefe, Bruyette & Woods. Keefe has a price target of $21 on the stock which represents 13% upside from the previous close of $18.58.
Continue reading “KeyCorp Stock Bullish Flag Flush On Analyst Buy Rating”

Global Blood Therapeutics Rising Large Players Volume

Global Blood Therapeutics stock has excellent large players volume action. Large players volume is in an uptrend and is confirmed by the rising Twiggs Money Flow.

Global Blood Therapeutics stock has 11 Buy ratings from analysts. Price targets average to $55.73 which represents 71.73% upside from the previous closing price. Needham & Company, one of the most followed analyst firms because of their excellent record, set a price target on the stock today of $51 which is 57% upside from the previous close at $32.45.
Continue reading “Global Blood Therapeutics Rising Large Players Volume”

Abbott Laboratories Stock Higher On Analysts Price Target Hikes

Abbott Laboratories stock is rising fast after reporting earnings. Four analysts reaffirmed or upgraded the stock to a Buy or Outperform rating after Abbott Laboratories earnings report beat on both earnings and revenue.

The company reported earnings of $0.66 versus the $0.65 estimate. Revenue also beat coming in at $6.83 billion versus the $6.72 billion estimate. Abbott Laboratories had a net margin of 4.96% and a return on equity of 14.43%. Abbott Laboratories’s revenue for the quarter was up 28.8% on a year-over-year basis.
Continue reading “Abbott Laboratories Stock Higher On Analysts Price Target Hikes”

Huntington Ingalls Consolidates On Rising Large Players Volume

Huntington Ingalls Industries won a contract for conducting engineered overhaul of fiscal 2019 USS Boise (SSN 764), from the Naval Sea Systems Command. The contract is valued at $59.8 million. This contract has a potential to reach a cumulative value of $385.7 million.
Continue reading “Huntington Ingalls Consolidates On Rising Large Players Volume”

Ingredion Stock Price Continuation Pattern On Seasonal Play

Ingredion stock price could move over the next 12 weeks if its seasonal pattern holds. Over the next 12 weeks, Ingredion stock price has on average risen by 12% based on the past 19 years of stock performance. Ingredion has risen higher in 17 of those 19 years over the next 12 week period, corresponding to a probability of 89%.
Continue reading “Ingredion Stock Price Continuation Pattern On Seasonal Play”

Exelixis Gets FDA Priority Review for Cabomteyx

The FDA has granted priority review for Exelixis Cabomteyx. The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma (RCC). The FDA determined the sNDA to be sufficiently complete. This means an FDA approval decision will be made by Feb. 15, 2018.
Continue reading “Exelixis Gets FDA Priority Review for Cabomteyx”

Mindbody Inc Stock Rising Large Players Volume and Insider Buy

Mindbody Inc stock has rapidly rising large players volume on an insider buy from Luxor Capital Group (major shareholder). Luxor Capital Group bought 83,022 shares at $27.95 for a total value of $2,320,464.90. You can see the SEC form 4 filing here.
Continue reading “Mindbody Inc Stock Rising Large Players Volume and Insider Buy”